Yasushi Shimizu

Yasushi Shimizu

Auto-generated profile, based on publicly available information

Yasushi Shimizu

Department of Medical Oncology, Hokkaido University Hospital, Sapporo, Hokkaido, Japan

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2012 in Lung Cancer
Verified
Journal Article
Closed access
JKJunko Kikuchi
Junko Kikuchi
TTTaichi Takashina
Taichi Takashina
IKIchiro Kinoshita
Ichiro Kinoshita
EKEiki Kikuchi
Eiki Kikuchi
YSYasushi Shimizu
Yasushi Shimizu
HDHirotoshi Dosaka-Akita
Hirotoshi Dosaka-Akita

1 October 2017 in Oral Oncology
Verified
Journal Article
Open access
NKNAOMI KIYOTA
NAOMI KIYOTA
YHYasuhisa Hasegawa
Yasuhisa Hasegawa
STShunji Takahashi
Shunji Takahashi
TYTomoya Yokota
Tomoya Yokota
YCYen Chia-Jui
Yen Chia-Jui
MTMakoto Tahara
Makoto Tahara
To assess efficacy and safety of nivolumab versus investigator's choice of therapy (IC) in Asian patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Thirty-four patients from Japan, Taiwan, Hong Kong, and Korea received nivolumab 3mg/kg (n=23) every 2weeks or IC (n=11), as part of a global trial (n=361), until intolerable toxicity or disease progression. The primary endpoint was overall survival (OS). Median OS was 9.5months (95% confidence interval [CI] 9.1-NR) with nivolumab and 6.2months (95% CI 2.6-NR) with IC. Seven (30.4%) patients receiving nivolumab and six (54.5%) receiving IC died. The hazard ratio (HR) for risk of death (nivolumab vs. IC) was 0.50 (95% CI 0.17-1.48). Median progression-free survival was 1.9months (95% CI 1.6-7.5) with nivolumab and 1.8months (95% CI 0.4-6.1) with IC (HR 0.57 [95% CI 0.25-1.33]). Objective response rates (complete+partial responses) were 26.1% (6/23 patients; 95% CI 10.2-48.4) for nivolumab and 0% (0/11 patients; 95% CI 0.0-28.5) for IC. Sixteen (69.6%) nivolumab-treated patients and 10 (90.9%) patients receiving IC had a treatment-related adverse event, most commonly decreased appetite (21.7%), pruritus, rash, and fatigue (17.4% each) with nivolumab, and nausea, stomatitis, and decreased appetite (27.3% each) with IC. Nivolumab demonstrated a survival advantage compared with conventional treatments in Asian patients with platinum-refractory recurrent or metastatic SCCHN, and was well tolerated. Clinical trial registration NCT02105636.

1 May 2011 in Lung Cancer
Verified
Journal Article
Closed access
JKJunko Kikuchi
Junko Kikuchi
IKIchiro Kinoshita
Ichiro Kinoshita
YSYasushi Shimizu
Yasushi Shimizu
EKEiki Kikuchi
Eiki Kikuchi
KTKayoko Takeda
Kayoko Takeda
HDHirotoshi Dosaka-Akita
Hirotoshi Dosaka-Akita

1 January 2016 in World Journal of Gastrointestinal Oncology
Verified
Journal Article
Open access
YOYoshihito Ohhara
Yoshihito Ohhara
NFNaoki Fukuda
Naoki Fukuda
STSatoshi Takeuchi
Satoshi Takeuchi
RHRio Honma
Rio Honma
YSYasushi Shimizu
Yasushi Shimizu
HDHirotoshi Dosaka-Akita
Hirotoshi Dosaka-Akita
Role of targeted therapy in metastatic colorectal cancer

11 June 2010 in Cancer
Verified
Journal Article
Open access
PDF file
JKJunko Kikuchi
Junko Kikuchi
IKIchiro Kinoshita
Ichiro Kinoshita
YSYasushi Shimizu
Yasushi Shimizu
EKEiki Kikuchi
Eiki Kikuchi
JKJun Konishi
Jun Konishi
HDHirotoshi Dosaka‐Akita
Hirotoshi Dosaka‐Akita
BACKGROUND: The polycomb group genes Bmi1 polycomb ring finger oncogene (Bmi1) and enhancer of zeste homolog 2 (EZH2) function as transcriptional repressors involved in gene silencing and in the malignant transformation and biologic aggressiveness of several human carcinomas. In the current study, the authors evaluated Bmi1 and EZH2 protein expression in specimens of human nonsmall cell lung cancer (NSCLC). METHODS: The authors conducted an immunohistochemical assessment of 157 surgically resected NSCLCs to evaluate the correlation between Bmi1 and EZH2 expression and various features, including clinical, clinicopathologic, and biologic characteristics. RESULTS: Normal bronchial epithelia revealed abundant expression of Bmi1 and sporadic expression of EZH2. Patients who had high EZH2 expression in tumor cells had a poorer prognosis than patients who had low EZH2 expression in tumor cells all pathologic stages of NSCLC (P = .001) and in pathologic stage I NSCLC (P = .006). Multivariate analysis revealed that high EZH2 expression was a independent, unfavorable prognostic factor in patients with pathologic stage I disease (P = .048). High EZH2 expression was correlated significantly with nonadenocarcinoma histology (P = .001), moderate and poor differentiation (P = .001), advanced pathologic tumor classification (P = .02), and high Ki‐67 and cyclin E labeling indices (P < .001). Bmi1 expression, in contrast, was not a significant prognostic factor and was not correlated with any clinicopathologic factors other than early pathologic tumor classification. CONCLUSIONS: Bmi1 and EZH2 had characteristic and distinctive expression in NSCLCs. High EZH2 expression was correlated with tumor aggressiveness and may provide a novel prognostic marker for NSCLCs. Cancer 2010. © 2010 American Cancer Society.

13 June 2016 in Cancer Science
Verified
Journal Article
Open access
TTTaichi Takashina
Taichi Takashina
IKIchiro Kinoshita
Ichiro Kinoshita
JKJunko Kikuchi
Junko Kikuchi
YSYasushi Shimizu
Yasushi Shimizu
JSJun Sakakibara‐Konishi
Jun Sakakibara‐Konishi
HDHirotoshi Dosaka‐Akita
Hirotoshi Dosaka‐Akita
Recent discoveries have revealed that human cancer involves aberrant epigenetic alterations. We and others have previously shown that the histone methyltransferase EZH2, the catalytic subunit of polycomb repressive complex 2 (PRC2), is frequently overexpressed in non‐small‐cell lung cancer (NSCLC) and that an EZH2 inhibitor, 3‐deazaneplanocin A, inhibits the proliferation of NSCLC cells. Transcriptional silencing by EZH2 was recently shown to be required for the activity of histone deacetylases (HDACs) that interact with another PRC2 protein, EED. To develop a more effective epigenetic therapy for NSCLC, we determined the effects of co‐treatment with 3‐deazaneplanocin A and the HDAC inhibitor vorinostat (SAHA) in NSCLC cells. The co‐treatment synergistically suppressed the proliferation of all tested NSCLC cell lines, regardless of their epidermal growth factor receptor (EGFR) status. The synergistic effect was associated with slightly decreased histone H3 lysine 27 trimethylation, modestly increased histone acetylation, and the depletion of EZH2 and other PRC2 proteins. The co‐treatment resulted in an accumulation of p27Kip1, decrease in cyclin A, and increased apoptotic fraction in an additive/synergistic manner. Interestingly, the co‐treatment strongly suppressed EGFR signaling, not only in EGFR‐wild‐type NSCLC cells, but also in EGFR‐mutant cells, mainly through dephosphorylation of EGFR. Furthermore, the co‐treatment suppressed the in vivo tumor growth of EGFR‐mutant, EGFR–tyrosine kinase‐resistant H1975 cells more effectively than did each agent alone, without visible toxicity. These results suggest that the combined pharmacological targeting of EZH2 and HDACs may provide more effective epigenetic therapeutics for NSCLC.